336 related articles for article (PubMed ID: 15830252)
41. Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health.
Neaton JD; Babiker A; Bohnhorst M; Darbyshire J; Denning E; Frishman A; Grarup J; Larson G; Lundgren J
Clin Trials; 2010 Dec; 7(6):705-18. PubMed ID: 20729252
[TBL] [Abstract][Full Text] [Related]
42. [Approval of clinical trials of immunobiological medicinal products at the Paul Ehrlich Institute].
Krafft H; Cichutek K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):168-72. PubMed ID: 15726457
[TBL] [Abstract][Full Text] [Related]
43. CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation?
Barbui C; Cipriani A; Lintas C; Bertelé V; Garattini S
Psychopharmacology (Berl); 2007 Feb; 190(2):265-8. PubMed ID: 17119928
[No Abstract] [Full Text] [Related]
44. Effects of EU harmonization policies on national public supervision of clinical trials: A dynamic cycle of institutional change and institutional work.
van Oijen JCF; Grit KJ; van de Bovenkamp HM; Bal RA
Health Policy; 2017 Sep; 121(9):971-977. PubMed ID: 28733068
[TBL] [Abstract][Full Text] [Related]
45. GCP inspections in Germany and Europe following the implementation of the Directive 2001/20/EC.
Göbel C; Baier D; Ruhfus B; Hundt F
Ger Med Sci; 2009 Mar; 7():Doc01. PubMed ID: 19675741
[TBL] [Abstract][Full Text] [Related]
46. [Clinical trials for children].
Boos J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):530-5. PubMed ID: 15887062
[TBL] [Abstract][Full Text] [Related]
47. Harmonising and competing for medicines regulation: how healthy are the European Union's systems of drug approval?
Abraham J; Lewis G
Soc Sci Med; 1999 Jun; 48(11):1655-67. PubMed ID: 10400264
[TBL] [Abstract][Full Text] [Related]
48. [Fundamental principles of clinical trials].
Skarke C; Geisslinger G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):401-7. PubMed ID: 15830250
[TBL] [Abstract][Full Text] [Related]
49. Regulatory requirements for clinical trial and marketing authorisation application for gene therapy medicinal products.
Schüle S; Renner M; Longhurst S; Narayanan G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):30-7. PubMed ID: 20012927
[TBL] [Abstract][Full Text] [Related]
50. [Clinical research. Effects of European legislation and current developments].
Sudhop T; Enzmann H; Klar R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):375-6. PubMed ID: 19343281
[No Abstract] [Full Text] [Related]
51. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use: an overview.
Petrini C
Ann Ist Super Sanita; 2014; 50(4):317-21. PubMed ID: 25522070
[TBL] [Abstract][Full Text] [Related]
52. Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries.
Gluud C; Kubiak C; Whitfield K; Byrne J; Huemer KH; Thirstrup S; Libersa C; Barraud B; Grählert X; Dreier G; Geismann S; Kuchinke W; Temesvari Z; Blasko G; Kardos G; O'Brien T; Cooney M; Gaynor S; Schieppati A; de Andres F; Sanz N; Kreis G; Asker-Hagelberg C; Johansson H; Bourne S; Asghar A; Husson JM; Demotes-Mainard J
Trials; 2012 Mar; 13():27. PubMed ID: 22452964
[TBL] [Abstract][Full Text] [Related]
53. European activities in radiation protection in medicine.
Simeonov G
Radiat Prot Dosimetry; 2015 Jul; 165(1-4):34-8. PubMed ID: 25870434
[TBL] [Abstract][Full Text] [Related]
54. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
Lehmann B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
[TBL] [Abstract][Full Text] [Related]
55. [Changes in the German Medicinal Product Act imposed by the EU regulation on clinical trials].
Nickel L; Seibel Y; Frech M; Sudhop T
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):804-811. PubMed ID: 28664271
[TBL] [Abstract][Full Text] [Related]
56. Will the Europe Union's Traditional Herbal Medicinal Products Directive (Directive 2004/24/EC) be against traditional Chinese medicine in EU market?
Xu J; Liu M; Xia Z
J Evid Based Med; 2013 May; 6(2):104-8. PubMed ID: 23829802
[TBL] [Abstract][Full Text] [Related]
57. The use of community herbal monographs to facilitate registrations and authorisations of herbal medicinal products in the European Union 2004-2012.
Peschel W
J Ethnopharmacol; 2014 Dec; 158 Pt B():471-86. PubMed ID: 25043780
[TBL] [Abstract][Full Text] [Related]
58. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use.
Med Etika Bioet; 2002; 9(1-2):12-9. PubMed ID: 16276663
[No Abstract] [Full Text] [Related]
59. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
60. Regulations applicable to plant food supplements and related products in the European Union.
Silano V; Coppens P; Larrañaga-Guetaria A; Minghetti P; Roth-Ehrang R
Food Funct; 2011 Dec; 2(12):710-9. PubMed ID: 21997496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
